Divis Laboratories, a leading pharmaceutical company, released its Q3 results, showcasing a robust performance. The consolidated net profit for the quarter ending December 2023 surged to Rs 358 crore, marking a substantial 17% increase from the previous year's Rs 306 crore.
In terms of revenue, the company recorded a 9% year-on-year growth, reaching Rs 1,855 crore compared to Rs 1,708 crore in the corresponding period last year. This growth in revenue contributed to an impressive EBITDA of Rs 489 crore, marking a noteworthy 20% increase from the previous year's Rs 409 crore. Moreover, the company's margins saw an improvement, standing at 26.4%.
The Profit before Tax (PBT) for the quarter was reported at Rs 489 crore, showcasing a substantial increase from the previous year's Rs 435 crore during the corresponding quarter.
Overall, Divis Laboratories continues to exhibit strong financial performance, underlining its position as a key player in the pharmaceutical industry.
إرسال تعليق